AnodyneWiki

Escitalopram

Escitalopram
Escitalopram
Salts
[]
Escitalopram oxalate
Escitalopram oxalate
Escitalopram hydrobromide
Escitalopram hydrobromide
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass324.40 g/mol [1]
Melting point147-152C [1]
SolubilitySparingly soluble [1]
Predicted LogP3.2 [1]
Structural Identifiers
[]
Molecular formulaC20H21FN2O
IUPAC name(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
SMILESCN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
InChIInChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1
InChIKeyWSEQXVZVJXJVFP-FQEVSTJZSA-N
CAS number128196-01-0
UNII4O4S742ANY
PubChem CID146570
Pharmacokinetics[]
Elimination half-life~27–32 hours
MetabolismLiver (CYP2C19, CYP3A4, CYP2D6)
ExcretionUrine (major; 8–10% unchanged), feces (minor)
Routes of administrationBy mouth

Escitalopram (also known as (S)-Citalopram, S(+)-Citalopram, Cipralex, Seroplex, S-(+)-Citalopram, Esertia, (+)-Citalopram, Esitol, escitalopramum or (+)-(S)-1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile) is a substance of the alkylbenzene class.

Chemistry

Salts []

Escitalopram is typically found in the form of its oxalate and hydrobromide salts.

 []

Escitalopram is a single defined stereoisomer (optical activity ( + )).

Escitalopram matches Lipinski's rule of five.

Pharmacology

Mechanism of action []

Escitalopram, like other selective serotonin re-uptake inhibitors, enhances serotonergic activity by binding to the orthosteric (i.e. primary) binding site on the serotonin transporter (SERT), the same site to which endogenous 5-HT binds, and thus prevents the re-uptake of serotonin into the presynaptic neuron. Escitalopram, along with [paroxetine], is also considered an allosteric serotonin re-uptake inhibitor - it binds to a secondary allosteric site on the SERT molecule to more strongly inhibit 5-HT re-uptake. Its combination of orthosteric and allosteric activity on SERT allows for greater extracellular 5-HT levels, a faster onset of action, and greater efficacy as compared to other SSRIs. The sustained elevation of synaptic 5-HT eventually causes desensitization of 5-HT<sub>1A</sub> auto-receptors, which normally shut down endogenous 5-HT release in the presence of excess 5-HT - this desensitization may be necessary for the full clinical effect of SSRIs and may be responsible for their typically prolonged onset of action. Escitalopram has shown little-to-no binding affinity at a number of other receptors, such as histamine and muscarinic receptors, and minor activity at these off-targets may explain some of its adverse effects. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

metabolism / inhibition / induction365 (15 contraindicated)
metabolism / induction / inhibition259 (4 contraindicated)
metabolism / inhibition / induction95 (2 contraindicated)
shared target60
metabolism3

Subjective effects []

a1ko / Escitalopram []
Routes:
  • Oral (50mg)
magnus / Escitalopram []
Routes:
  • Oral

Experience reports

Reddit

There are currently 4 trip reports involving escitalopram on : []

 []

  • Australia: Escitalopram is a Schedule 4.[3]
  • Brazil: Escitalopram is a C1.[4]
  • Canada: Escitalopram is Prescription only.
  • United Kingdom: Escitalopram is Prescription only.
  • United States: Escitalopram is Prescription only.[5]
  • European Union: Escitalopram is Prescription only.[6]
  • Other: Escitalopram is a Rx-only.

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 146570, Escitalopram. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/146570
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Escitalopram. UNII: 4O4S742ANY. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/4O4S742ANY
  3. Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. Therapeutic Goods Administration. 21 June 2022. https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017
  4. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
  5. Lexapro- escitalopram tablet, film coated; Lexapro- escitalopram solution. DailyMed. 17 November 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13bb8267-1cab-43e5-acae-55a4d957630a
  6. Active substance(s): escitalopram. List of nationally authorised medicinal products. September 2022. https://www.ema.europa.eu/documents/psusa/escitalopram-list-nationally-authorised-medicinal-products-psusa/00001265/202112_en.pdf

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 09:34:31
drugspromissing (no DrugsPRO reagent data)2026-11-20 09:34:27
erowidmissing (no Erowid substance of that name)2026-11-20 09:34:27
gsrsok2026-11-20 09:34:29
hmdbmissing (hmdb.ca refused automated access to HMDB0005028)2026-11-20 09:34:27
keggok2026-11-20 09:34:31
pubchemok2026-11-20 09:34:27
redditok2026-11-20 09:34:27
sidermissing (not in SIDER)2026-11-20 09:34:27
structureok2026-11-20 09:34:27
wikipediaok2026-11-20 09:34:28